| Document |
Document Title |
|
WO/2024/060271A1 |
Provided are a characteristic impurity in an empagliflozin bulk drug or preparation and use thereof, and further provided are a detection method, a synthesis method, in-vitro pharmacological activity and in-vitro toxicity of the impurity...
|
|
WO/2024/024760A1 |
The purpose of the present invention is to provide a highly stable pyrazolone compound. This problem can be solved by a pyrazolone compound represented by formula (1) of the present invention (in the formula, R1 is an electron-withdraw...
|
|
WO/2024/010959A1 |
Novel compounds and methods of using the compounds are provided herein. The compounds include novel carbon analogs of pyranose derivatives discovered to have Toll- like receptor 4 (Tlr4) inhibitory activity. The methods provide for treat...
|
|
WO/2023/201008A1 |
Disclosed herein are compositions and methods for metabolically labeling cells using click chemistry reagents. The compositions and methods disclosed herein provide a specific and efficient means of localizing desired agents, such as ant...
|
|
WO/2023/142238A1 |
SGLT2 inhibitor intermediate V-1 and the use thereof. The present invention specifically relates to an intermediate as represented by formula V-1 and the use thereof in the preparation of an SGLT2 inhibitor. The intermediate and a method...
|
|
WO/2023/080243A1 |
One purpose of the present invention is to provide a novel thioester derivative and a method for producing the same, a novel ketone derivative and a method for producing the same, a novel method for producing a C-arylhydroxyglucoside der...
|
|
WO/2023/002509A1 |
The present disclosure provides a formulation comprising a first lipid compound of Formula I; a second lipid compound of Formula II and a co-lipid wherein the first lipid to the second lipid to the co-lipid is in the mole ratio range of ...
|
|
WO/2022/265964A1 |
Described herein are orally-bioavailable nucleoside analogs and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of coronavirus infections, including SARS-CoV-2 in...
|
|
WO/2022/251677A1 |
Disclosed herein are macrolide compounds with ATP synthase inhibitory activity. The macrolides may be used to treat cancer and other proliferative disorders. The macrolides may be used to treat leukemia, including acute myeloid leukemia....
|
|
WO/2022/224015A1 |
An improved method for the chemical synthesis of glycosylated peptides has been developed. The method uses stereoselective glycan synthesis and chemical peptide ligation to produce glycopeptides at lower-cost and with higher efficiency/y...
|
|
WO/2022/221870A1 |
The present disclosure describes methods of preparing carbanucleosides.
|
|
WO/2022/160737A1 |
The present invention relates to a crystal form of a tetrahydropyran ring compound and a preparation method therefor. Specifically disclosed are the polymorphism of the compound represented by formula (I), and a preparation method for th...
|
|
WO/2022/157233A1 |
The present invention relates to compounds of the following formula (I): as well as their preparation process; their use in cosmetic or dermatological applications, in particular for the treatment and/or prevention of skin aging, skin pr...
|
|
WO/2022/135173A1 |
Provided is an Escherichia coli strain, H03A2190830. The deposit number thereof is CCTCC NO: M2019900. Further provided are a method for producing a polysialic acid by means of using the Escherichia coli, and a method for producing a sia...
|
|
WO/2022/124859A1 |
The present invention relates to a 1'-homoadenosne derivative, and a pharmaceutical composition for preventing or treating hypoadiponectinemia-associated diseases or psoriasis, containing same as an active ingredient, and provides: a 1'-...
|
|
WO/2022/119541A1 |
The present invention relates to a film coated tablet formulation comprising dapagliflozin and metformin hydrochloride wherein dapagliflozine has a d (0.9) particle size between 20 µm to 140 µm. Further, the present invention also rela...
|
|
WO/2022/078974A1 |
The present disclosure relates generally to malonyl steviol glycosides and the use of such compounds for various comestible uses, such as sweetening a flavored product or enhancing the sweetness of another sweetener. In some aspects, the...
|
|
WO/2022/067724A1 |
Provided are an SGLT-2 inhibitor sarcosine co-crystal, a preparation method therefor and use thereof. Using sarcosine as a ligand, said co-crystal has higher safety and lower costs; a drug co-crystal has higher stability, and during the ...
|
|
WO/2021/233314A1 |
Provided is a method for economically and efficiently preparing β-D-(1,4)-mannuronate oligosaccharide as represented by formula (IX). Particularly, the method comprises: using economical and easily available 1,2,3,4,6-penta-O-acetyl-D-m...
|
|
WO/2021/197363A1 |
The present invention relates to a 2-alkynyl mannose derivative and an application thereof. The mannose derivative, as well as a pharmaceutically acceptable salt, an isotope and an isomer thereof have the structure represented by general...
|
|
WO/2021/183750A2 |
The present disclosure generally describes methods of preparing l'-cyano nucleosides, such as a compound of Formula (I). For example, the compound of Formula (I) can be prepared from a compound of Formula (Il-a) in a flow reactor.
|
|
WO/2021/175296A1 |
The present invention provides an intermediate of Remdesivir and a preparation method therefor. The preparation method has the advantages of low costs, high yield, good product purity, etc. , and can achieve the efficient synthesis of Re...
|
|
WO/2021/168004A1 |
The present disclosure describes 4'-fluoromethyl nucleosides for treating viral infections, including Dengue.
|
|
WO/2021/105779A1 |
The present invention relates to solid compounds also referred to as new solid forms (NSF) of Dapagliflozin (DPG) co-crystals and co-amorphs, wherein the co-former is selected from: a) a carboxylic acid derivative having an amino group i...
|
|
WO/2021/073064A1 |
A method for improving the yield rate of an Amadori rearrangement product (ARP) on the basis of a mechanism of inhibiting degradation of the ARP by an adduct of a tea polyphenol and deoxyosone. The specific method comprises: dissolving a...
|
|
WO/2021/054474A1 |
In the present invention, a disaccharide unit for synthesizing a useful sugar chain for suppressing the development of dystroglycanopathy is obtained and used to reconstitute a post-phosphoryl sugar chain. Provided are: a disaccharide ...
|
|
WO/2021/055753A1 |
Methods for inhibiting CMP-sialic acid synthetases and other CMP-sugar synthetases using sugar derivatives such as dehydro-sugars and anhydro-sugars are described, as well as methods for treating conditions including bacterial infections...
|
|
WO/2021/018044A1 |
Compounds as SGLT2/DPP4 dual inhibitors, and application in preparation of medicines as the SGLT2/DPP4 dual inhibitors. A compound represented by formula (I), and an isomer or pharmaceutically acceptable salt thereof are specifically inv...
|
|
WO/2021/019509A1 |
The present document relates to a process for the preparation of the crystalline form II of sotagliflozin from compound of formula (A), said process being continuously performed and comprising at least the steps of: a) performing in a re...
|
|
WO/2021/019507A1 |
The present document relates to a process for the preparation of the crystallineform II of sotagliflozin, wherein said crystalline form II of sotagliflozin is directly obtained from the following compound of formula (A) and by using tolu...
|
|
WO/2021/004498A1 |
It relates to glucopyranosyl derivative of formula (I) as a sodium-dependent glucose transporters1 (SGLT1) inhibitor, a pharmaceutically acceptable salt, or a stereoisomer thereof, and further relates to a pharmaceutical composition cont...
|
|
WO/2020/242253A1 |
The present invention relates to a novel empagliflozin derivative, which is a novel compound that is useful as an SGLT-2 inhibitor. In addition, a novel empagliflozin derivative according to the present invention exhibits a relatively hi...
|
|
WO/2020/211668A1 |
Disclosed are compounds that are inhibitors of CD73 and are useful in treating CD73-associated diseases or conditions, and compositions containing the compounds.
|
|
WO/2020/204691A1 |
The present invention discloses a functionalized glycolipid having a formula (I): (I) where Y is selected from a group consisting of O, NH and NAc; wherein A is selected from a group of bi-antennary hydrophobic domain having a formula (I...
|
|
WO/2020/129901A1 |
[Problem] To provide a novel method for preparing a ketone compound. [Solution] Provided is a method for preparing compound (I) represented by formula (I), the method comprising a step for obtaining compound (I) by reacting compound (II)...
|
|
WO/2020/083871A1 |
The present invention relates to novel oligogalacturonans having a degree of methylation of 0 and a degree of polymerisation of 1 to 10, and to the use thereof for stimulating defence responses of plants against pathogenic microorganisms.
|
|
WO/2020/061129A1 |
Disclosed herein are compositions and methods for labeling cells using click chemistry reagents. The compositions and methods disclosed herein provide a specific and efficient means of localizing desired agents to a variety of cell types...
|
|
WO/2020/040433A1 |
The present invention relates to a method for preparation of a dapagliflozin precursor, which is a SGLT-2 inhibitor and, particularly, to a method for preparation of the dapagliflozin precursor, which is the compound of chemical formula ...
|
|
WO/2020/036382A1 |
The present invention relates to a method for producing an intermediate useful for the synthesis of a diphenylmethane derivative that can be used as a SGLT inhibitor. A method for synthesizing a compound of formula 7 according to the pre...
|
|
WO/2020/002076A1 |
The present invention relates to the cosmetic use, as moisturizer for keratin materials, preferably the skin, of one or more 5-oxazolidine-2,4-dione C-glycoside derivatives corresponding to formula (I) below, and also the solvates and/or...
|
|
WO/2020/001812A1 |
The present invention relates to a novel process for the preparation of SGLT-2 inhibitors via addition of a hydroxymethylene group in an open chain intermediate, readily accessible from D-glucose.
|
|
WO/2020/002054A1 |
The present invention relates to a process for the cosmetic treatment of keratin materials, comprising the application to said materials, such as the skin, of a composition comprising a compound (I) The invention relates in particular to...
|
|
WO/2019/151128A1 |
A cell labeling agent according to the present invention includes a monosaccharide derivative having a six-membered ring structure metabolized by sialic acid in a sialic acid biosynthesis pathway of a cell. Among groups bonded to carbon ...
|
|
WO/2019/115616A1 |
The present invention relates to Novel 1,7-dicarba-closo- dodecaborane(12) (meta-carbaborane)-derived carboxylic acids suitable for peptide modification for application in boron neutron capture therapy (BNCT).
|
|
WO/2019/115617A1 |
The present invention relates to Novel 1,7-dicarba-closo-dodecaborane (meta-carbaborane)-derived carboxylic acids and amines according to Formula (I) suitable for peptide modification for application in boron neutron capture therapy (BNC...
|
|
WO/2019/106122A1 |
The invention describes novel conjugates of formula (I) of a pharmaceutical agent and a moiety capable of binding to a glucose sensing protein allowing a reversible release of the pharmaceutical agent depending on the glucose concentration.
|
|
WO/2019/043069A1 |
The present invention relates to a new class of sucrose esters and a method for their preparation.
|
|
WO/2018/207111A1 |
The present invention relates to an industrially feasible and economically viable process for preparation of SGLT2 inhibitors of formula (X) in significantly high yield and purity.
|
|
WO/2018/163194A1 |
The present invention relates to a process for the preparation of D-glucitol, 1,5- anhydro-1-C-[4-chloro-3-[[ 4-[[(3S)-tetrahydro-3-furanyl)oxy )phenyl] methyl]phenyl]-, (IS) formula-1.
|
|
WO/2018/155970A1 |
The present invention relates to a novel glucose derivative, and said novel compound is useful as an SGLT-2 inhibitor. In addition, the novel glucose derivative according to the present invention has a relatively higher melting point, lo...
|
